Geode Capital Management, LLC Cellectar Biosciences, Inc. Transaction History

Geode Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$3.5 - $6.9 $8,862 - $17,470	2,532 Added 0.57%	444,415 $179,000
Q3 2021 Nov 12, 2021	BUY	$8.2 - $12.4 $366,646 - $554,441	44,713 Added 11.26%	441,883 $408,000
Q2 2021 Aug 13, 2021	BUY	$11.8 - $18.2 $1.8 Million - $2.78 Million	152,778 Added 62.51%	397,170 $472,000
Q1 2021 May 12, 2021	BUY	$15.2 - $25.0 $1.7 Million - $2.8 Million	111,997 Added 84.59%	244,392 $393,000
Q4 2020 Feb 12, 2021	BUY	$11.2 - $27.7 $1.48 Million - $3.67 Million	132,395 New	132,395 $275,000
Q3 2018 Nov 13, 2018	SELL	$21.9 - $79.0 $1.59 Million - $5.72 Million	-72,383 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$62.0 - $125.0 $4.49 Million - $9.05 Million	72,383 New	72,383 $44,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.